Medical Oncologist
ALK-positive lung cancer
When Alectinib Stops Working: — Resistance and What Comes Next
Most ALK-positive lung cancers respond well to alectinib, often for years. When the disease progresses, it is usually because the cancer has found a way around the drug — and knowing which way matters, because the next treatment depends on it.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Resistance has two main types — The cancer can develop a new ALK mutation, or it can switch to a completely different signalling pathway that alectinib does not block.
- Re-biopsy guides what comes next — NCCN and ESMO guidance recommends re-testing tumour tissue or a blood sample at progression, because the resistance mechanism determines the best next step.
- Lorlatinib is the main next-line option — For ALK-dependent resistance, lorlatinib — a third-generation ALK inhibitor — is the most established option and is included in NCCN guidance.
- Chemotherapy remains active — If the cancer has shifted to a pathway that ALK inhibitors cannot target, platinum-based chemotherapy is an effective alternative.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
When alectinib stops working, the most common next step is lorlatinib, a third-generation ALK inhibitor that can overcome many of the mutations that cause resistance. Which treatment fits best depends on the resistance mechanism, which is why NCCN and ESMO guidance recommends re-biopsy or a liquid biopsy before choosing the next line.
Why does alectinib eventually stop working?
Alectinib works by blocking a protein called ALK, which is driving the cancer's growth. Over time, cancer cells can change in ways that let them get around that block.
The most common route is a new mutation in the ALK gene itself. Mutations at positions such as G1202R, I1171, and V1180 alter the shape of the ALK protein so that alectinib can no longer bind to it effectively.
A second route is bypass signalling. Here the cancer stops relying on ALK altogether and activates a different growth pathway — such as MET amplification or EGFR changes — that alectinib has no effect on.
In a small number of cases, the cancer undergoes a more fundamental change called histological transformation, where it begins to behave like a different tumour type, most often small-cell lung cancer. This is rare, but it is one reason why a repeat biopsy at progression gives information that a scan alone cannot.
What should happen when your scan shows progression on alectinib?
Tell your team about new or worsening symptoms
Progression sometimes shows on a scan before you notice anything. But new pain, breathlessness, or headaches are also signals your team needs to know about promptly rather than waiting for the next scheduled visit.
Re-biopsy or liquid biopsy
Your oncologist will typically recommend sampling the progressing tumour — through a tissue biopsy or a blood-based liquid biopsy — to look for the resistance mechanism. This test is what drives the next treatment decision.
Molecular testing of the new sample
The sample is tested for new ALK mutations and for changes in other pathways such as MET and EGFR. Results usually take one to two weeks, and they may require a specialised laboratory.
Multidisciplinary team review
An oncologist, radiologist, and molecular pathologist review the results together to agree the best next-line option for your specific resistance profile. Treatment choice is not made from imaging alone.
Start next-line treatment
Treatment begins once the team has a clear picture of what is driving progression. Starting before results are back risks choosing a treatment that does not match the resistance mechanism.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
You do not have to work this out alone
A 45-minute consultation with a specialist who treats this every week.
What are the options if the cancer still has an ALK mutation?
If testing shows a new ALK mutation, the cancer remains ALK-dependent. That means a more potent ALK inhibitor is the right direction rather than switching away from ALK targeting entirely.
Lorlatinib is a third-generation ALK inhibitor designed specifically to overcome many of the resistance mutations that develop on alectinib, including G1202R. NCCN guidelines include lorlatinib as a recommended option after progression on a second-generation ALK inhibitor, and ESMO guidance is consistent with this.
Some people develop what are called compound mutations — two mutations in the ALK gene at the same time. These are more difficult to treat and can limit the effectiveness of lorlatinib. Clinical trial participation is particularly worth discussing in that situation.
Your oncologist will explain what the specific mutation found in your biopsy means and whether lorlatinib is the right choice for your result.
What if the cancer has moved to a different pathway?
If testing shows the cancer is no longer driven by ALK — because it has activated MET or EGFR signalling, or has transformed to small-cell — the approach shifts away from ALK inhibitors.
For bypass signalling through a targetable pathway such as MET amplification, adding or switching to an agent that targets that pathway may be appropriate, depending on what is available and guideline-recommended. Your oncologist will advise on what applies to your specific result.
For small-cell transformation, chemotherapy regimens used in small-cell lung cancer become the relevant approach.
For resistance without a clearly targetable driver, platinum-based chemotherapy remains an established and active option. It is not a last resort — it has a meaningful chance of response in ALK-positive lung cancer.
Questions families commonly ask at this point
Does progression on alectinib mean the cancer is now untreatable?
No. Progression on one drug does not mean the cancer has run out of options. ALK-positive lung cancer has more approved treatment lines than most other types, and the sequence from alectinib to lorlatinib to chemotherapy is well-established in NCCN and ESMO guidance. The goal at each step is to understand why the current treatment stopped working and to match the next treatment to that specific reason. Many people go through multiple lines and continue to have good periods of disease control.
Is lorlatinib available in India?
Lorlatinib has received regulatory approval from CDSCO and is available in India, though access and cost vary by centre and insurance status. It is a prescription medicine that requires oncologist supervision and regular monitoring for specific side effects. Ask your oncologist whether it is the right option for your resistance profile, and ask about assistance programmes or insurance coverage at the same time. Your CION team can advise on what is available at your treatment centre.
Can the liquid biopsy replace a tissue biopsy at progression?
A liquid biopsy — a blood test that looks for cancer DNA circulating in the bloodstream — can detect many ALK resistance mutations without a needle biopsy. It is less invasive and often faster. However, it can miss mutations that a tissue sample would catch, particularly when the tumour is not shedding much DNA into the blood. ESMO guidance describes liquid biopsy as a valid first step at progression, with tissue biopsy recommended when the blood test is negative or inconclusive. Your oncologist will advise on which is appropriate in your situation.
Should we look at a clinical trial?
Yes, and particularly when the resistance mechanism is complex — for example a compound ALK mutation, or a bypass pathway without a clearly approved targeted option. Clinical trials in ALK-positive lung cancer continue to enrol in India, and they offer access to agents not yet commercially available. Your oncologist can check which trials are open at your centre or at a nearby referral centre. Joining a trial does not mean forgoing standard care; most trials allow standard treatment as a comparator or fallback.
What if the scan shows progression in only one or two spots?
When progression is limited to one or two areas while other sites remain controlled — a pattern sometimes called oligoprogression — NCCN and ESMO describe local treatment such as stereotactic radiotherapy or surgery to those specific sites, while continuing alectinib. This is not a routine option for all patients; it requires careful discussion and depends on where the spots are and how the rest of the disease looks. If your scans show this pattern, ask your oncologist directly whether local therapy alongside continuing alectinib is worth considering before switching systemic treatment.
Does the cancer become more aggressive after alectinib resistance?
Not necessarily, and this fear is worth naming directly. Progression on one agent does not mean the cancer has become more aggressive overall. What changes is that the current treatment is no longer controlling it — but the next treatment may control it well. The biology of ALK-positive lung cancer gives it more active treatment lines than most other types, and many people have extended periods of disease control on second and third-line treatments. Your oncologist can tell you what the behaviour of your specific cancer suggests, which is more informative than a general prediction.
Explore 75 more Lung Cancer Targeted Medicines topics
Drug Deep Dive: Alectinib (Alecensa)
- Alectinib (Alecensa, Alectinib): The Complete Patient Guide
- Alectinib After Surgery for Early-Stage ALK-Positive Lung Cancer
- Alectinib Myths: Is ALK-Positive Cancer 'Curable'?
- Alectinib Price in India: Brand, Generic and Monthly Cost
- Alectinib Side Effects: The Complete List and Timeline
- Alectinib Success Rate and Survival: An Honest Look at the Numbers
- Alectinib and Brain Metastases: How It Protects the Brain
- Alectinib in Elderly Patients and Those With Other Illnesses
- Alectinib vs Crizotinib vs Lorlatinib: Choosing an ALK Inhibitor
- Diet and Nutrition While on Alectinib
- Do You Need Chemotherapy Alongside Alectinib?
- Drug, Food and Supplement Interactions With Alectinib
- Fertility, Pregnancy and Contraception on Alectinib
- How Does Alectinib Work? The Second-Generation ALK Inhibitor Explained
- How Long Does Alectinib Take to Work?
- How Long Will You Stay on Alectinib?
- Muscle Pain and High CPK on Alectinib: When to Worry
- Severe Sun Sensitivity on Alectinib: Preventing Serious Burns
- Taking Alectinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Alectinib
- Weight Gain, Constipation and a Slow Pulse on Alectinib
- When Alectinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Alectinib? ALK-Positive Lung Cancer
- Will Insurance or a Government Scheme Pay for Alectinib?
- Work, Travel and Daily Life on Alectinib
Drug Deep Dive: Gefitinib (Iressa)
- Diarrhoea on Gefitinib: Home Management and Warning Signs
- Diet and Nutrition While on Gefitinib
- Fertility, Pregnancy and Contraception on Gefitinib
- Gefitinib (Iressa, Geftinat, Geftib): The Complete Patient Guide
- Gefitinib Myths: 'It's Only for Poor Patients' and Other Half-Truths
- Gefitinib Plus Chemotherapy: Does Adding Chemo Actually Help?
- Gefitinib Price in India: Brand, Generic and Monthly Cost
- Gefitinib Rash: Why It Appears in Week Two and How to Treat It
- Gefitinib Side Effects: The Complete List and Timeline
- Gefitinib Success Rate and Survival: An Honest Look at the Numbers
- Gefitinib and Antacids: The Interaction That Silently Reduces Absorption
- Gefitinib in Early-Stage vs Advanced Lung Cancer: Different Goals
- Gefitinib in Elderly Patients and Those With Other Illnesses
- Gefitinib vs Osimertinib: Making the Decision When Cost Matters
- How Does Gefitinib Work? The First-Generation EGFR Inhibitor Explained
- How Long Does Gefitinib Take to Work?
- How Long Will You Stay on Gefitinib?
- Raised Liver Enzymes on Gefitinib: What Your LFT Report Means
- T790M Testing After Gefitinib Stops Working: The Next Step Explained
- Taking Gefitinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Gefitinib
- When Gefitinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Gefitinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Gefitinib?
- Work, Travel and Daily Life on Gefitinib
Drug Deep Dive: Osimertinib (Tagrisso)
- Adjuvant Osimertinib After Lung Cancer Surgery: Three Years of Tablets
- Breathlessness or New Cough on Osimertinib: Recognising Lung Injury (ILD)
- Diet and Nutrition While on Osimertinib
- Drug, Food and Supplement Interactions With Osimertinib
- Fertility, Pregnancy and Contraception on Osimertinib
- Heart Rhythm and Ejection Fraction Changes on Osimertinib
- How Does Osimertinib Work? The Third-Generation EGFR Inhibitor Explained
- How Long Does Osimertinib Take to Work?
- How Long Will You Stay on Osimertinib?
- Osimertinib (Tagrisso): The Complete Patient Guide
- Osimertinib Myths: Clear Scans, Stopping Early and Generic Quality
- Osimertinib Price in India: Brand, Generic and Monthly Cost
- Osimertinib Side Effects: The Complete List and Timeline
- Osimertinib Success Rate and Survival: An Honest Look at the Numbers
- Osimertinib With Chemotherapy: Who Actually Benefits From the Combination?
- Osimertinib and Brain Metastases: Why It Works Inside the Brain
- Osimertinib in Elderly Patients and Those With Other Illnesses
- Osimertinib vs Gefitinib and Erlotinib: Is the Costlier Drug Worth It?
- Rash, Dry Skin and Nail Problems on Osimertinib
- Taking Osimertinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Osimertinib
- When Osimertinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Osimertinib? EGFR-Mutant Lung Cancer
- Will Insurance or a Government Scheme Pay for Osimertinib?
- Work, Travel and Daily Life on Osimertinib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
How do I know if my alectinib has stopped working?
The clearest sign is a change on your imaging scan — a tumour growing larger, a new spot appearing, or fluid where it was not before. Symptom changes such as new or worsening breathlessness, pain, or neurological symptoms can also signal progression. Do not wait for your next scheduled scan if symptoms are changing: call your oncology team so they can decide whether an earlier scan is needed. Routine monitoring scans are specifically designed to catch progression before symptoms become severe.
Will my doctor know which resistance mechanism I have without a biopsy?
Usually not. The scan can show that the disease is progressing, but it cannot show why. Two patients whose scans look identical at progression can have completely different resistance mechanisms — one with a new ALK mutation that lorlatinib can overcome, and one with bypass signalling that needs a different approach. This is why a repeat biopsy or liquid biopsy is a standard recommendation at progression rather than an optional extra. Choosing the next treatment without knowing the mechanism means choosing without the most important piece of information.
Is there a third ALK inhibitor after lorlatinib?
Lorlatinib is currently the most advanced commercially available ALK inhibitor, and its use after alectinib is the established sequence in NCCN and ESMO guidance. Beyond lorlatinib, the options shift toward chemotherapy and, where appropriate, clinical trials. Several next-generation compounds are in development specifically to address lorlatinib resistance — including agents targeting compound mutations — but none has regulatory approval in India at the time this was written. This is an active area of research, and trial participation is particularly worth discussing in this situation.
Can the cancer become sensitive to alectinib again after a break?
Re-sensitisation — where a cancer that became resistant to a drug responds again after a period off it — has been described for some targeted therapies, but it is not predictable or reliable enough to plan treatment around for alectinib. There is no established guidance recommending rechallenge with alectinib after confirmed resistance. If a treating oncologist raises this as an option, it would typically be in the context of a clinical trial or a very specific clinical situation, not as a routine next step.
How long does the next treatment after alectinib usually work?
There is no figure reliable enough to quote for an individual, and any number you see needs to be interpreted carefully because it reflects average data from clinical trial populations that may not match your specific resistance profile. What is consistent in NCCN-referenced evidence is that lorlatinib produces meaningful disease control in a proportion of patients who progressed on earlier-generation ALK inhibitors. Your oncologist is the right person to discuss what the trial data suggests for a resistance profile like yours and what realistic goals of treatment look like in your case.
What should I ask my oncologist when they tell me alectinib is not working?
Ask four things. First: what does the scan show exactly — where is it progressing and by how much? Second: are you recommending a re-biopsy or liquid biopsy, and what are you looking for? Third: once results are back, which treatment will you recommend and why? Fourth: are there clinical trials I should know about for my specific resistance profile? Writing these down before the appointment helps, because this is a difficult conversation to hold in memory afterwards. Bringing someone with you is also worth doing if you can.